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Accumulating evidence suggests that hypothalamo-pituitary-thyroid (HPT) axis dysfunction is relevant to the pathophysiology
and clinical course of bipolar aﬀective disorder. Hypothyroidism, either overt or more commonly subclinical, appears to the
commonestabnormalityfoundinbipolardisorder.Theprevalenceofthyroiddysfunctionisalsolikelytobegreateramongpatients
with rapid cycling and other refractory forms of the disorder. Lithium-treatment has potent antithyroid eﬀects and can induce
hypothyroidism or exacerbate a preexisting hypothyroid state. Even minor perturbations of the HPT axis may aﬀect the outcome
of bipolar disorder, necessitating careful monitoring of thyroid functions of patients on treatment. Supplementation with high
dose thyroxine can be considered in some patients with treatment-refractory bipolar disorder. Neurotransmitter, neuroimaging,
and genetic studies have begun to provide clues, which could lead to an improved understanding of the thyroid-bipolar disorder
connection, and more optimal ways of managing this potentially disabling condition.
1.Introduction
The association between thyroid functions and behavioural
disturbances has been known for the last several hundred
years. Although the eﬀects of thyroid hormones on the
developing brain were recognised long ago, recent advances
in biotechnology have led to an improved understanding
of the impact of thyroid functions on the adult, mature
brain [1]. This development has been particularly helpful in
elucidatingtheroleofthyroidhormonesinthepathophysiol-
ogy of psychiatric disorders, especially mood disorders. The
primaryfocusofinteresthasbeenontheconnectionbetween
thyroid functions and depressive disorders. However, abnor-
malities of thyroid functions may also play an important
role in the pathophysiology of bipolar aﬀective disorder, but
this area has received much less attention than it probably
deserves.
This paper attempts to explore the links between thyroid
hormone physiology and the presentation and pathogenesis
of bipolar disorder. It brieﬂy covers several areas of overlap,
beginning with the association of bipolar disorders with
thyroid disease among clinical and epidemiological popu-
lations, as well as the evidence of hypothalamo-pituitary-
thyroid (HPT) axis abnormalities among patients with
bipolar disorder. Rapid cycling and other refractory forms
of bipolar disorder have been particularly highlighted, since
the prevalence of thyroid dysfunction appears to be greater
in such forms of the disorder. The research relating to
the widespread and potent antithyroid eﬀects of lithium
carbonate, the drug most commonly used for treating
bipolar disorder, has been summarised next. The role of
thyroid hormones in the treatment of bipolar disorder is
also reviewed. Although the evidence supporting the use of
adjunctive thyroid hormone treatment of bipolar disorder is
somewhat meagre, such strategies may be useful in a subset
of patients with chronic and refractory forms of bipolar
disorder. Despite rapid strides made in uncovering cellular
and molecular mechanisms of actions of thyroid hormones,
the speciﬁc neurobiological processes that underlie the mod-
ulatory eﬀect of thyroid hormones in mood disorders are far
from clear. Animal studies have provided considerable data
onthereciprocalinteractionsbetweenthyroidhormonesand
neurotransmitter systems believed to play a role in genesis
of mood disorders [2]. These studies provide the basis for
several hypotheses (included in this paper), which propose
that the modulatory eﬀects of thyroid hormones on mood
are mediated by their actions on diﬀerent neurotransmitter
systems. A brief mention has also been made of genetic and
neuroimaging investigations that are beginning to attract
considerable attention, since they can oﬀer vital clues to the2 Journal of Thyroid Research
link between thyroid dysfunction and bipolar disorder. The
paperendswithadiscussionofthepertinentmethodological
issuesandsuggestionsforfutureresearch,whichcanenhance
our understanding of the thyroid-bipolar disorder link.
2.The HPT Axis
The organization and regulation of the HPT system has
been extensively reviewed elsewhere [1–8]. Hence, only
the relevant aspects are described here. The thyroid gland
is the largest endocrine organ in the human body. The
thyroid regulates cellular activity by releasing two diﬀerent
hormones, the prohormone thyroxine (T4) and the biolog-
ically active triiodothyronine (T3). The HPT system has a
hierarchical structure similar to that of the hypothalamo-
pituitary adrenal axis, with the thyrotropin-releasing hor-
mone (TRH) as the hypothalamic master hormone. TRH
is released from nerve endings in the median eminence;
from here it enters the anterior pituitary through the portal
system. In the pituitary, TRH induces synthesis and release
of thyrotropin or the thyroid-stimulating hormone (TSH),
from thyrotrophs. TSH enters the circulation and acts on the
thyroid gland causing release of T3 and T4.
All T4 comes from the thyroid, but, under usual circum-
stances, only about 20% of T3 is derived from the gland.
The remaining 80% comes from the removal of iodine from
the T4 molecule by enzymes called deiodinases. Type-II
deiodinase converts T4 to T3. This enzyme is located mostly
in glial cells of various regions of the brain, principally the
cortical areas and the anterior pituitary. The activity of type
II deiodinase is primarily responsible for regulating brain
T3 concentrations. The actions of thyroid hormones at the
cellular level are initiated by the intracellular binding of T3
to nuclear thyroid hormone receptors. These receptors are
widely distributed in the adult brain, with higher densities
in phylogenetically younger brain regions (e.g., amygdala
and hippocampus), and lower densities in the brain stem
and cerebellum. The entry of T3 into the cell is mediated
by two plasma membrane carriers, the monocarboxylate
transporter and the organic anion-transporting polypep-
tide. After the coupling of T3 to nuclear receptors, the
transcriptionally active complex binds to thyroid hormone-
responsive elements located on thyroid hormone-responsive
genes.Thisbindingproducesconformationalchangesinthy-
roid hormone responsive genes, which initiates a sequence
of transcription of messenger ribonucleic acid, increased
gene expression, and synthesis of proteins. Although the
mechanisms of thyroid hormone eﬀects on the brain are
not fully known, they probably include genomic actions,
an eﬀect on neurotransmission directly at the synapse, and
modulation of neurotransmitter systems and intracellular
signalling pathways.
The HPT axis is regulated by several complex feedback
mechanisms at all levels. Unbound or free T3 and T4 feed
back at the level of the hypothalamus to inhibit TRH release,
and at the anterior pituitary level to inhibit TSH release.
Diﬀerent neurotransmitters and hormones either promote
or inhibit release of TRH and TSH. The HPT axis is also
regulated by stress-responsive elements, which inﬂuence
TRH levels, and by the circadian system’s inﬂuence on
TSH. At the level of brain, additional mechanisms such as
circulating levels of T3 and T4, intracellular transport, and
deiodinase activity regulate local concentrations of thyroid
hormones. Consequently, levels of T3 within the brain are
tightly controlled within narrow limits, even under adverse
conditions [1–8].
3. Thyroid Diseaseand Bipolar Disorder
Neuropsychiatric symptoms, such as mood disturbances and
cognitive impairment, are very common among patients
with thyroid disorders.
Hyperthyroidism or thyrotoxicosis is usually associated
with symptoms such as anxiety, depression, mood lability,
and insomnia in a majority of the patients. However, overt
psychiatric disorder is rare and occurs in only about 10% of
the patients [1, 5]. Manic episodes have been known to occur
in patients with hyperthyroidism, but are quite unusual [9].
Occasionally, patients with late-onset mania are detected to
havehyperthyroidism,whichrequirestobetreatedtoachieve
full recovery [10]. Nevertheless, patients who develop a
true manic episode while thyrotoxic, frequently have an
underlying mood disorder, or a family history of mood
disorder [11, 12]. Manic episodes can also result from the
relatively uncommon phenomenon of lithium carbonate-
associated thyrotoxicosis [9, 13]. Lithium may induce thy-
rotoxicosis by several mechanisms including triggering of
theautoimmuneprocesswithresultantthyroiditis,abnormal
iodine kinetics, that is, overﬂow of thyroid hormone after
expansion of the intrathyroid iodine pool, Jod-Basedow-like
phenomenon, direct toxicity to thyroid follicles resulting in
releaseofthyroglobulin,andcoincidentalGraves’diseaseand
hyperthyroidism [14–16].
Psychiatric symptoms in hyperthyroidism, such as anx-
iety or mania, appear to be mediated by beta-adrenergic
hyperactivity. Accordingly, psychiatric symptoms and psy-
chiatric disorders secondary to hyperthyroidism should be
ﬁrst treated by restoring the euthyroid state. Additional
treatment with beta-adrenergic antagonists is also helpful.
Antimanic agents are required only when symptoms fail to
respond to these measures [8].
The most common psychiatric symptoms related to
hypothyroidism are depression and cognitive dysfunction
[1, 3, 8]. Only a few instances of mania or hypomania
associated with hypothyroidism have been reported in
the literature [17]. Underlying mechanisms are less clear;
they could include dysregulation of CNS catecholamine
receptor sensitivity, associated thyroditis and thyrotoxicosis,
or a disruption of circadian rhythms [18]. A retrospective
review based on 18 patients described an organic aﬀective
syndrome-manic type occurring shortly after the initia-
tion of thyroid replacement in hypothyroid patients [19].
Patients experiencing mania were predominantly female,
often had concurrent psychotic symptoms, frequently had a
personal or familial history of psychiatric disorder, and had
received more than 150mcg/day of thyroxine. The authors
suggested that rapid administration of thyroxine could
abruptlyaugmentcatecholaminereceptorsensitivity,therebyJournal of Thyroid Research 3
precipitating a hypercatecholaminergic state and subse-
quent manic symptoms. Similar instances of T3-induced
mania in patients with bipolar depression have also been
reported [20]. It has been speculated that thyroid hormone-
catecholamine receptor interactions might underlie these
T3-associated clinical manifestations as well [20].
Even though thyroid disorders are associated with psy-
chiatric symptoms in clinical populations, existence of a
similar association in general population is less certain. On
one hand, are the reports of a positive association between
thyroid disease and mood disorders in some community
studies. For example, a group of investigators at Copenhagen
conducted prospective cohort studies utilising historical data
from Danish case registers to determine the association
b e t w e e nt h y r o i da n da ﬀective disorders [21–23]. In separate
reports, it was demonstrated that patients hospitalised with
bipolar disorder tended to be at a greater risk of re-
admission with hyperthyroidism than controls [21], while
patients hospitalised with hyperthyroidism were at greater
risk of readmission with depressive disorder or bipolar
disorder than controls [22]. Finally, patients hospitalized
with hypothyroidism also had a greater risk of readmission
with depression or bipolar disorder, than control patients
[23]. These reports thus provided strong epidemiological
support for a link between thyroid disease and mood
disorders, including bipolar disorder. Further evidence for
this association came from two other studies. The ﬁrst
such study was based on analysis of a series of insurance
claims for inpatient hospitalisation, physician oﬃce visits,
and laboratory testing [24]. These data were used to estimate
the risk of having a comorbid condition among patients with
bipolar disorder. In this study, the risk of hypothyroidism
among bipolar patients was twice that of those with no
mental health disorders. Another multicentric study from
France included 1090 patients with bipolar I disorder, 9% of
whom had rapid cycling bipolar disorder (RCBD). Exami-
nation of comorbid medical conditions revealed that among
the various physical disorders, only thyroid disorders were
associated with rapid cycling [25]. On the other hand, quite
a few other investigations of medical comorbidity among
patients with bipolar disorder have not found a signiﬁcant
increase in the prevalence of thyroid disorders [26–28].
In conclusion, even though both hyperthyroidism and
hypothyroidism are associated with changes in mood, overt
bipolar disorder is uncommon in thyroid dysfunction.
M o r e o v e r ,d a t af r o mc o m m u n i t y - b a s e ds a m p l e s ,i nc o n t r a s t
to clinical samples, provide conﬂicting results regarding the
association between thyroid diseases and bipolar disorder.
4. HPTAxis Dysfunctionin Bipolar Disorder
Although HPT axis dysfunction appears to be equally
relevant for the pathophysiology of bipolar disorder, as it
is for depressive disorders, this subject has received far less
attention from researchers. However, there is now growing
evidence of all manner of thyroid abnormalities in patients
with bipolar disorder, which often far exceed those found
among patients with unipolar depression [1, 3, 5, 29, 30]. As
discussed subsequently, thyroid dysfunction is particularly
common in patients with the rapid cycling variant of
bipolar disorder. However, the antithyroid action of mood-
stabilisers, particularly lithium carbonate, frequently con-
founds the ﬁndings among patients with bipolar disorder.
Accordingly, there is some uncertainty about the true extent
of HPT abnormalities in bipolar disorder and the proportion
of HPT dysfunction that can be attributed to lithium-
treatment [1, 5, 29].
Overt hyperthyroidism is uncommon in bipolar disor-
d e r ;i t sp r e v a l e n c ei sn og r e a t e rt h a n2 %a c r o s sd i ﬀerent
studies [13, 15, 31]. Much of this has been attributed to
lithium [32], which can induce thyrotoxicosis by autoim-
mune mechanisms or thyroiditis [14–16]. A transient ele-
vation of T4 or free T4 levels has often been noted among
patients with mania shortly after hospitalization [33–36].
These levels gradually normalize after a few weeks of
treatment, as patients achieve remission. There is some
suggestion that elevated T4 levels following hospitalisation
are positively associated with severity of symptoms, and
that the rate of fall in these levels is linked to a better
outcome [34, 36, 37]. However, this ﬁnding is not speciﬁc
to mania, as transient mild elevations of free and total
T4 (“euthyroid hyperthyroxinemia”) have been commonly
noted in acutely admitted psychiatric patients, including
those with depression. This indicates that such elevations
a r em o r el i k e l yt ob en o n s p e c i ﬁ ce ﬀects of the stress of
hospitalisation [3, 38]. Currently, the most diagnostically
sensitive tests to detect thyroid dysfunction are the ultra-
sensitive immunoradiometric assays of serum TSH [39].
However, prior to the development of highly speciﬁc and
sensitive TSH assays, the TSH response to an intravenous
dose of TSH was the most widely used test for detecting HPT
dysfunction. The response is exaggerated in hypothyroidism
and blunted in hyperthyroidism. A blunted TSH response
occursin25–30%ofpatientswithunipolarmajordepression
[40]. However, blunted TSH responses to TRH may be
far more common among patients with bipolar disorder,
including those with mania [41, 42], bipolar depression
[43, 44], and rapid cycling disorder [45]. Moreover, the
severity of mood symptoms and milder ﬂuctuations in these
symptoms has been found to correlate with blunted TSH
responses to TRH [46]. On the other hand, many patients
with bipolar disorder may show an exaggerated response of
TSH to TRH [47]. This is often associated with elevated
basal serum TSH levels; approximately 20% of the patients
have levels above the upper normal reference range [48,
49]. Exaggerated TSH responses, along with elevated basal
levels of TSH, have also been noted among patients with
rapid cycling and are consistent with the high prevalence
of subclinical hypothyroidism often found in this condition
[3, 29]. Gyulai et al. [50] found that patients with RCBD
did not diﬀer from controls on any of thyroid function
tests prior to treatment with lithium. However, after 4
weeks of lithium-treatment, exaggerated TSH responses to
TRH were signiﬁcantly more common among such patients.
They, thus, proposed that RCBD is associated with a latent
hypofunction of the HPT system, which becomes manifest
with lithium treatment. Given lithium’s antithyroid actions,
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to TRH stimulation is extremely common and has been
reported in 50–100% of lithium-treated patients [51]. Then
again, evidence of overt or subclinical hypothyroidism,
including raised antibody titres, has often been found
among patients with bipolar disorder, prior to treatment
with lithium [31, 52, 53]. Accordingly, it appears that, at
least in a subgroup of patients with bipolar disorder, treat-
ment with lithium, rather than inducing hypothyroidism,
actually exacerbates a preexisting (overt) HPT dysfunction
[32].
In summary, HPT axis abnormalities are quite common
among patients with bipolar disorder. However, there are
several concerns regarding the speciﬁcity of these abnormal-
ities, and the eﬀect of lithium in inducing HPT dysfunction
in bipolar disorder.
5. HPTAxisDysfunctioninRapid Cycling
B ipo l arD is o r d e ran dM ix edA f f ec ti v eS t at e s
Rapid cycling usually aﬀects about 9 to 20% of all patients
with bipolar disorder [25, 54–56]. This subpopulation is
characterized by more severe morbidity and a refractory
clinical course. More women, than men, suﬀer from rapid
cycling [54, 55].
Ofallthepotentialriskfactorsforrapidcycling,hypothy-
roidism has received the most attention. All categories of
H P Ta x i sd y s f u n c t i o n sh a v eb e e nr e p o r t e di nR C B D .T h e s e
have included overt hypothyroidism [29, 57–59], elevated
TSH levels [58, 60–62], exaggerated TSH responses to
TRH [62], elevated antibody titres [63], and antidepressant-
induced rapid cycling [41, 58]. However, methodological
problems such as retrospective designs, lack of controls,
predominance of female subjects, and varying deﬁnitions of
hypothyroidism have all hindered any consistent conclusions
from these data [50]. Moreover, a number of other studies
have been unable to document this association [45, 52,
53, 64–68], promoting considerable scepticism about the
presence of HPT axis abnormalities in RCBD [54, 55, 68,
69]. More pertinently, many of the studies reporting a
positive association have included patients being treated
with lithium. Lithium treatment clearly contributes to the
development of hypothyroidism among patients with rapid
cycling [50, 70]. In this regard, the study by Gyulai et al.
[50] is of some signiﬁcance. Their contention that RCBD
is associated with a latent hypofunction of the HPT system,
which becomes manifest with short-term lithium challenge,
remains a possibility. (The wide ranging anti-thyroid eﬀects
of lithium are described in the next section.) A latent
hypofunction of the thyroid axis in RCBD may also explain
whyhighdosesofT4addedtotheestablishedtreatmentwith
lithium and other psychotropic drugs can reverse the rapid
cycling pattern [1, 5].
Mixed aﬀective states have also been associated with
reduced thyroid functioning in certain studies. In a study of
ﬁrst-episodemanicandmixedtypesofbipolardisorder,33%
of the patients in mixed episodes had elevated TSH levels,
in comparison with 7% of patients experiencing pure mania
[71]. In similar vein, Chang et al. [72] found signiﬁcantly
lower T4 levels and elevated TSH levels in patients with
mixed mania, compared with those with pure mania. These
diﬀerences were not associated with exposure to lithium.
Others have reported that patients with mixed states have
a higher rate of positive anti-thyroid antibody titres, than
other unipolar or bipolar subgroups, apparently unrelated
to lithium treatment [73, 74]. However, not all studies have
been able to conﬁrm the association of overt or subclinical
thyroid dysfunction with mixed manic episodes [75, 76].
Thus, the question of HPT dysfunction in mixed aﬀective
states remains an unresolved one [69].
To conclude, the prevalence of HPT dysfunction is very
high among patients with RCBD. Despite concerns about
methodology, contrary ﬁndings and confounding eﬀects
of lithium-treatment, the existence of a latent thyroid dys-
function in RCBD, which is exacerbated by lithium, re-
mains a possibility. In contrast, the evidence linking HPT
dysfunction and mixed aﬀective states is inadequate and
inconsistent.
6. Lithiumand HPTAxisDysfunction
The anti-thyroid eﬀects of lithium carbonate are well docu-
mented [51, 77, 78]. The mechanisms by which lithium can
cause hypothyroidism are complex. Lithium is concentrated
by the thyroid gland and inhibits thyroidal iodine uptake.
It also inhibits iodotyrosine coupling, alters thyroglobulin
structure, inhibits thyroid hormone secretion [51], and
interferes with the deiodination of T4 to T3 by inhibiting
type-II deiodinase in the brain [79]. Lithium may evoke an
exaggerated TSH response to TRH [51]. The drug may have
an immunostimulant eﬀect, either by inducing, or by exacer-
bating a preexisting autoimmune disease [32, 80]. Addition-
ally, lithium alters cellular responsiveness to thyroxine, and
inﬂuences thyroid hormone receptor gene expression [81].
Inhibition of thyroidhormone release, a process mediated by
cyclic adenosine monophosphate, appears to be the critical
mechanisminthedevelopmentoflithium-inducedhypothy-
roidism [32]. Compensatory mechanisms may operate to
prevent the development of hypothyroidism or goitre in
the majority of patients with lithium-induced impairments
in thyroxine secretion. However, when additional risk fac-
tors such as iodine deﬁciency, preexisting autoimmunity,
or genetic vulnerability are present, such compensatory
mechanisms fail and hypothyroidism eventually ensues
[32].
Rates of overt hypothyroidism vary from 0 to 47% (aver-
age of about 10%) among patients on long-term treatment
with lithium [32, 80, 82, 83]. Diﬀerences in study design,
deﬁnitions of hypothyroidism, age, gender, and geographical
origin of patients, are often responsible for such wide
variations in rates. Nevertheless, both the incidence and
prevalence of overt hypothyroidism is signiﬁcantly higher
among patients on lithium, compared to general population
ﬁgures [32]. The average duration of lithium therapy before
the diagnosis of hypothyroidism is around 18 months [83],
though there are a few reports of hypothyroidism occurring
within the ﬁrst few months of lithium-treatment [84, 85].
Female gender, middle age (>50 years), preexisting autoim-
munity, and family history of thyroid diseases are establishedJournal of Thyroid Research 5
risk factors for lithium-induced hypothyroidism [82, 83, 86,
87]. An even larger number of patients appear to develop
subclinical hypothyroidism. Low or normal T4 levels and
elevated TSH levels are reported among 5 to 35% (average
of about 25%) patients on lithium [88], while exaggerated
TSH responses are found among 50%, or more, of such
patients [51, 89]. Cross-sectional studies of lithium-induced
goitre reveal a prevalence of 0 to 60% [51]; prevalence
estimates are much higher (30–59%) when more sensitive
ultrasonographicscansareusedtodetectincreasesinthyroid
volumes [32, 87, 90]. Several studies of patients on lithium
have found an elevated rate of anti-thyroid antibodies,
ranging from about 8 to 49% in such patients; these rates
were signiﬁcantly higher than those among control patients
or the general population [84, 89, 91–100]. An almost equal
number of studies have failed to ﬁnd an association between
elevated antibody titres and exposure to lithium [32, 53, 73,
74, 101–104]. Studies are similarly inconsistent as to whether
thyroid antibodies are elevated in bipolar disorder, unrelated
to lithium-treatment; reported rates range from 0 to 43%
among patients with bipolar disorder not on lithium. Some
controlled comparisons have reported a higher prevalence
of thyroid antibodies in bipolar disorder [73, 74, 105],
especially in depressed and mixed states [73, 74], and RCBD
[63]. In the largest study of this kind, Kupka et al. [53]f o u n d
thyroperoxidase antibodies in 64 of 226 (28%) outpatients
with bipolar disorder, a rate higher than general population
subjects and patients with other psychiatric disorders. The
presence of anti-thyroid antibodies among patients with
bipolar disorder was associated with thyroid failure, but
not with age, gender, mood state, rapid cycling, or lithium
exposure[53].However,severalothercontrolledstudieshave
not been able to ﬁnd a higher prevalence of raised antibody
tires in bipolar disorder, unrelated to lithium treatment
[64, 103, 106].
To summarise, anti-thyroid actions of lithium are diverse
and complex. Rates of overt and subclinical hypothyroidism,
goitre, and raised antibody titres all appear to be signif-
icantly higher among patients on lithium, compared to
the general population and nonbipolar controls. However,
prospective studies have shown that elevated rates of thyroid
hypofunction continue to decline with continued lithium
treatment. Consequently, the prevalence of lithium-induced
hypothyroidism begins to approximate rates among general
population, after several years of lithium treatment, even
in the absence of thyroid supplementation [32, 88]. The
development of hypothyroidism is, thus, not a contraindi-
cation to continuing lithium. Thyroxine supplementation
is recommended instead, even though there is considerable
disagreement about when T4 should be added. Nevertheless,
overt hypothyroidism, signiﬁcantly enlarged thyroid vol-
umes, clear evidence of subclinical pathology, and the pres-
ence of rapid cycling or treatment-resistance are unequivocal
indications for T4 supplementation. Baseline tests of thyroid
functions and size, and similar annual examinations are
essential for all patients on lithium. Closer monitoring is
r e c o m m e n d e dw h e nr i s kf a c t o r ss u c ha sf e m a l eg e n d e r ,
middle age, autoimmunity, or positive family history are
present [3, 32, 88, 107, 108].
7. HPT AxisDysfunction andOutcome
of Bipolar Disorder
Regardless of the controversies about the nature and extent
of HPT axis dysfunction in bipolar disorder, there is sub-
stantial evidence that even minor perturbations of thyroid
function play a signiﬁcant role in the clinical course,
treatment response, and outcome of bipolar disorder. For
example, studies have shown that among patients with
bipolar depression, a relatively elevated free T4 index in
men was associated with a faster response to antidepressants
and a shorter length of hospital-stay [109], while lower
free T4 values and higher TSH values were signiﬁcantly
associated with a poorer response during the initial phase
of treatment [110]. A similar relationship between T3 and
T4 levels and short-term outcome of mania has also been
demonstrated [33, 36]. Moreover, the long-term eﬃcacy
of lithium prophylaxis also seems to be determined by
alterations in the HPT axis. Higher T3 levels were found to
predict better response to lithium, and lesser likelihood of
depressive recurrences during the ﬁrst few years of lithium
treatment in a couple of studies [111, 112]. Additionally,
Frye et al. [85] reported that a lower mean serum level
of free T4 was associated with more aﬀective episodes
and greater severity of depression during the ﬁrst year
of lithium-treatment. More recently, a retrospective anal-
ysis has shown that lithium-treated subjects who required
an intervention for a depressive episode had signiﬁcantly
increasedmeanTSHlevels,incomparisontolithium-treated
subjects who did not require any intervention for depression
[113].
In conclusion, several HPT axis abnormalities, which
may have an important bearing on outcome, have been
documented during acute-phase treatment of bipolar dis-
order. Similar ﬁndings during maintenance-phase treatment
with lithium are consistent with the well-known anti-thyroid
eﬀects of lithium. Therefore, lithium-induced changes in
thyroid function, even within the normal range, are detri-
mental to its prophylactic eﬃcacy, especially with regard to
depressive symptoms [85, 110, 113]. The presence of HPT
dysfunction during lithium-treatment further underlines
the need for regular monitoring of thyroid functions and
rapid correction of any abnormalities that arise during such
treatment. It may also explain why T4 supplementation can
enhancetreatment-responseinsomepatientswithrefractory
mood disorders on lithium treatment.
8. Thyroid Hormone Supplementation
in Bipolar Disorders
The use of synthetic thyroid hormones T3 and T4 as sup-
plementary agents in aﬀective illness has a long history, with
the ﬁrst reports appearing in the late 1960s [1, 48]. How-
ever, the bulk of the studies have been carried out among
patients with depression, where mostly T3, and occasion-
ally T4, have been used to accelerate or augment antidepress-
ant treatment. Among patients with bipolar disorder,
supraphysiologicaldosesofT4havebeenusedtosupplement
prophylactic eﬃcacy of mood stabilizing treatments and6 Journal of Thyroid Research
to augment antidepressant treatment in patients with
treatment-refractory bipolar depression.
Stancer and Persad [114] were the ﬁrst to report the
eﬀects of supraphysiological doses of T4 used as the sole
prophylactic agent in RCBD. Such treatment was only
partially successful, with cessation of cycling in ﬁve of
the eight women included in their study, but not in the
two men. This study was followed by case reports which
suggested that addition of supraphysiological doses of T4
to mood stabilizing treatments was more likely to prevent
rapid cycling [115]. Bauer and Whybrow [116]c o n d u c t e d
the ﬁrst open-label trial of adjunctive supraphysiological
doses of T4 in 11 patients with treatment-refractory RCBD.
Adjunctive treatment with T4 reduced the severity of manic
and the depressive phases in both amplitude and frequency,
and even led to complete remission in some patients.
Of the four patients who subsequently underwent single-
or double-blind placebo substitution, three relapsed. In
responders, supranormal circulating levels of free thyroxine
were necessary to induce a clinical response. Side eﬀects
were minimal, and there were no signs or symptoms of
thyrotoxicosis. Subsequently, other open-label studies found
adjunctive treatment with supraphysiological doses of L-T4
to be eﬀective in the maintenance treatment of patients with
severe rapid cycling or resistant bipolar disorder, who did
not respond to standard measures [117, 118]. Thyroxine
was used in doses of 250–500mcg/day in these studies; the
goal was to achieve TSH suppression by increasing free T4
levels by >50% of pretreatment levels. Despite concerns
about adverse eﬀects, the treatment was rated favourably
by recipients and was well tolerated [119]. There was little
evidence of cardiovascular side eﬀects [116]. Moreover, the
risk of bone demineralisation was not increased among
women, even after several years of treatment [120–122].
In a separate set of open trials, supraphysiological doses
of T4 were used to augment antidepressant treatment among
treatment-resistant patients with bipolar depression [122–
124]. Augmentation of antidepressants with high dose T4
had a beneﬁcial eﬀect on depressive symptoms in this
group of refractory patients as well. The treatment was well
tolerated, the rise in T3 and T4 levels was minimal, and
no complications were reported [124, 125]. This pattern of
response was signiﬁcantly diﬀerent from healthy controls
administeredthyroxine[125].Twoofthemorerecentstudies
have attempted thyroid hormone augmentation of patients
with refractory bipolar depression using slightly diﬀerent
strategies. Łojko et al. [126] found addition of moderate
doses of T4 (100mcg/day) to be a successful augmenta-
tion strategy in female patients with bipolar depression,
who had had an unsatisfactory response to serotonergic
antidepressants. Another retrospective chart review of 125
patients with treatment-resistant bipolar depression showed
augmentation with high dose T3 to be highly eﬀective,
thoughthereweresomeconcernsaboutadverseeﬀectsofthis
treatment [127].
The mechanisms underlying successful treatment with
adjunctive T4 are as yet unclear. Earlier, it was suggested
that adjunctive T4 counteracts the eﬀects of subclinical
hypothyroidism on neuronal adaptation [4, 5]. However,
contrary to this notion, most patients who responded had
normal thyroid functions [123]. This has led to several
alternative hypotheses, such as correction of peripheral
resistance to thyroid hormones, correction of isolated CNS
hypothyroidism, and positive modulation of cathecholamin-
ergic systems by T4, being responsible for this beneﬁcial
eﬀect [123].
To summarise, there is some evidence favouring the
usefulness of T4 supplementation of mood stabilising treat-
ments in a subset of patients with chronic and refractory
forms of bipolar disorder. However, such evidence is still
meagre. There are no randomised controlled trials, and the
total number of patients included in existing studies is too
small. Therefore, this strategy can only be considered as a
treatmentoflastresortinpatientswhohavefailedtorespond
to all other measures.
When augmentation is attempted, thyroxine is usually
started at 50–100mcg/day and increased by 25–50mcg
per week, to a maximum of 500mcg per day. Response
to treatment is usually evident within the ﬁrst 2 weeks.
Treatment is continued in responders for a few months.
In nonresponders, T4 is tapered oﬀ gradually, since abrupt
discontinuation can result in iatrogenic hypothyroidism.
Mostsideeﬀectscanbeavoidedtoagreatextentbygradually
building up the dose, adjusting it carefully, and monitoring
the patient closely. Special precautions are required in those
with endocrine or cardiovascular disorders. Administration
during pregnancy is not recommended. A careful lookout
should also be kept for the drugs being abused for their
weight reduction eﬀects [1, 3–5, 8].
9. HPT Axis Dysfunction and Bipolar Disorder:
UnderlyingNeurobiological Mechanisms
The mechanisms, by which thyroid dysfunction produces
mood symptoms, as well as those involved in amelioration
of mood symptoms by thyroid hormones, remain to be more
fully elaborated and understood. However, studies involving
neurotransmitter functions, genetics, and neuroimaging
haveuncoveredsomeofthecellularandmolecularprocesses,
which may explain the link between HPT axis dysfunction
and mood disorders.
9.1. Neurotransmitter Systems. T h er o l eo fs e v e r a ln e u r o -
transmitter systems including norepinephrine (NE), sero-
tonin(5-HT), dopamine (DA), and gamma aminobutyric
acid (GABA) in the pathogenesis of mood disorders is now
reasonably well established [128–130]. Interactions between
thyroid hormones and these neurotransmitter systems may
not only account for the psychiatric symptoms accompa-
nying thyroid disease, but also for the HPT dysfunction in
mood disorders, and the therapeutic actions of thyroid hor-
mones in mood disorders [1, 2, 5, 48, 49]. There are several
similarities between the HPT and neurotransmitter systems,
which endorse the possibility of mutual interactions. Firstly,
because of their common biosynthetic precursor tyrosine,
thyroid hormones (especially T3) are structurally similar to
NE and DA [131]. Moreover, both systems are present inJournal of Thyroid Research 7
key brain regions. Thyroid hormone receptors are widely
distributedinthebrain;manyofthelimbicsystemstructures
where these receptors are present have been implicated in
the pathogenesis of mood disorders. The neurotransmitter
systems originate in the brainstem and extend through the
midbrain into the limbic regions and the cortex. They
regulate mood by modulating the activity of these brain
areas [2, 5]. Finally, components of both systems appear to
coexist at the tissue level. Immunohistochemical mapping
studies have shown that T3 is concentrated in the nuclei and
projection sites of central noradrenergic systems [132], while
the thyroid gland exhibits GABA transport mechanisms, as
well as enzyme activities for GABA synthesis and degrada-
tion [133]. This suggests that thyroid hormones could act
as neurotransmitters and neuromodulators by themselves;
alternatively, their mood-regulatory properties could be
mediatedbyinteractionswiththeprincipalneurotransmitter
systems.
The interactions between thyroid and neurotransmit-
ter systems are often complex and reciprocal. Eﬀects of
neurotransmitter systems on TRH and TSH are better
characterised. NE stimulates both TRH and TSH release,
while 5-HT, DA, and GABA inhibit their release [134, 135].
On the other hand, evidence about the eﬀect of thyroid
hormones on neurotransmitters is mostly derived from
animal studies. Such evidence principally consists of altered
responsiveness of NE, 5-HT, DA, and GABA systems in the
adult/mature brain, resulting from experimentally induced
hypothyroid or hyperthyroid states [2, 5, 133, 136, 137]. In
addition, thyroid hormones also appear to have important
eﬀectsonintracellularsignaltransductionmechanisms,such
as G proteins, adenylate cyclase, and phosphoinositide-based
signallingpathwaysintheadultbrain[2,5].Apartfromthese
interactions in the mature brain, thyroid-neurotransmitter
interactions also play a signiﬁcant role in the developing
brain. Indeed, the actions of thyroid hormones on neuro-
transmittersystemsappeartobemorepronouncedinneona-
tal animals [2, 138], thus, underlining the important eﬀects
of thyroid hormones on formation and organization of
neurotransmitter systems in the developing brain [139–141].
The hypothesis that interactions between thyroid and
neurotransmitter systems may have a causal role in the
pathophysiology of mood disorders was originally proposed
by Whybrow and Prange [142]. They suggested that the
antidepressant properties of T3 could be explained by
its augmentation of postsynaptic beta-adrenergic activity.
Hypothyroidism was, thus, believed to cause depression by
producing a functional decrease in noradrenergic trans-
mission. The obverse of this would be mania caused by
a hyperadrenergic state. The reports of mania following
rapid administration of thyroid hormones described earlier
[19, 20] seem to support this possibility. The noradrenergic
hypothesis has since been modiﬁed to include the modulat-
ing inﬂuence of thyroid hormones on other neurotransmit-
ters. Research data, primarily from animal studies, indicate
similar eﬀects of thyroid hormones on the serotonin sys-
tem. Augmentation of serotonergic transmission by thyroid
hormones results from a combination of a reduction of the
sensitivity of 5-HT 1A autoreceptors in the raphe nuclei
and an increase in 5-HT 2 receptor density and sensitivity
in the cortex [2]. Additionally, neuroendocrine challenge
studies in hypothyroid patients have shown reduced 5-HT
responsiveness, which is reversible with thyroid replacement
therapy [2, 137]. Abnormalities of the 5-HT systems have
alsooccasionallybeenfoundamongpatientswithdepression
with documented HPT axis dysfunction [2, 137]. This
has led to the speculation that the serotonin system may
be involved in the mood-modulating eﬀects of thyroid
hormones among patients with mood disorders [2], and that
serotonin deﬁciency could account for several of the HPT
axis abnormalities observed in depression [48]. On similar
lines, it has also been suggested that disorders of dopamin-
ergic and GABAergic neurotransmission could account for
the psychiatric manifestations of thyroid dysfunction [137,
140], but, the evidence for such suppositions is insuﬃcient.
M o r e o v e r ,i ti sa p p a r e n tt h a tm u c ho ft h ee v i d e n c eo n
thyroid-neurotransmitter interactions is currently based on
animal studies. Studies among humans are scarce [137];
the few that have involved patients with mood disorders
have been limited to those with depression [2]. Thus,
though thyroid-neurotransmitter interactions seem to play a
role in the pathogenesis and treatment of mood disorders,
the speciﬁc interactions underlying modulatory eﬀects of
thyroid hormones among patients with bipolar disorder, are
yet to be clearly elucidated.
9.2. Neuroimaging Investigations. Newer ﬁndings from neu-
roimaging studies have suggested that HPT axis dysfunction
may be more fundamentally related to the aetiopathogenesis
of bipolar disorder. In a PET study of hypothyroid patients
undergoing thyroid hormone replacement, reduction of
the behavioural complaints during therapy was associated
with a restoration of metabolic activity in brain areas that
were integral to the regulation of aﬀect and cognition
[143]. Similarly, in another PET study of untreated Graves’
disease, thyrotoxicosis and attendant psychological symp-
toms were associated with regional metabolic changes of
limbic structures that mediate aﬀect [144]. These ﬁndings
have been complemented by neuroimaging investigations of
patients with bipolar disorder. In a seminal PET study of
medication-free, treatment-resistant patients with primarily
RCBD, serum TSH levels were inversely related to both
global and regional cerebral blood ﬂow, and cerebral glucose
metabolism [145]. These results suggested that relationships
between thyroid and cerebral activity could not only explain
HPT axis contributions to the genesis of bipolar disorders,
but, could also account for the therapeutic eﬀects of thyroid
hormones in bipolar disorders. In another study, ten women
with bipolar depression underwent PET, before and after
seven weeks of adjunctive treatment with supraphysiological
doses of L-T4 [123]. The authors found that patients with
bipolar depression had abnormal uptake in prefrontal and
limbic brain areas, in structures integral to aﬀect regulation,
which have been speciﬁcally implicated in bipolar disorder.
Administration of thyroxine appeared to improve mood
by aﬀecting circuits involving the very same areas. The
role of autoimmunity in development of cerebral perfu-
sion abnormalities in patients with thyroid disease is still8 Journal of Thyroid Research
unclear. However, SPECT studies of asymptomatic, euthy-
roid patients with autoimmune (Hashimoto’s) thyroiditis
hadearlierrevealedahighprevalenceofmildbrainperfusion
abnormalities [146, 147]. More recently, cortical perfusion
asymmetry (particularly between frontal lobes) was found
in a SPECT study of a patient with bipolar disorder and
Hashimoto’s thyroiditis, leading the authors to hypothesize
that abnormalities in cortical blood ﬂow might represent a
pathogenic link between thyroid autoimmunity and bipolar
disorders [148].
9.3. Genetic Investigations. One of the key recent develop-
ments in this area has been the research evidence suggesting
that HPT abnormalities may be a potential endopheno-
types for bipolar disorder. Vonk et al. [149]c o m p a r e d
the prevalence of thyroperoxidase antibodies among 22
monozygotic twins and 29 dizygotic twins with bipolar
disorder, with 35 healthy control twins. Antibody titres
were positive in 27% of the twins with bipolar disorder,
compared to only 16% in healthy control twins. The authors
proposed that autoimmune thyroiditis (with raised antibody
titres as markers) could be an endophenotype for bipolar
disorder and could be related to the genetic vulnerability
to develop bipolar disorder. In another study, a signiﬁcantly
higher prevalence of thyroperoxidase antibody titres was
predominantly found in daughters of parents with bipolar
disorder, compared to the female high school and young
adult comparisons [150]. Therefore, children of parents with
bipolardisorderwerefoundtobemorevulnerabletodevelop
thyroid autoimmunity, independently of their vulnerabil-
ity to develop psychiatric disorders. Coincidentally, recent
studies have found HPT abnormalities among children with
severe aﬀective, behavioural, and cognitive impairments,
who could be a part of the broad behavioural phenotype of
bipolar disorder [151].
Additionally, a few recent studies utilising genetic variant
analysis have also attempted to elucidate elements of HPT
axis dysfunction underlying thyroid-mood disorder interac-
tions [7]. For example, in a case-control association study of
Chinese patients, genetic variations of the type II deiodinase
gene were associated with bipolar disorder [152]. Moreover,
animal studies have shown that genetic mechanisms are
involved in regulation of striatal physiology by T3; this
could explain the beneﬁcial eﬀects of thyroid hormones in
mood disorders [153]. Genetic mechanisms have also been
invoked to explain lithium-induced hypothyroidism [154].
Although the research is still at a preliminary stage, these
ﬁndings suggest that genetic investigations are more likely to
eventually unravel the link between thyroid dysfunction and
bipolar disorder.
10.Methodological Issues
Despite the impressive advances made in research on HPT
axis dysfunction in abnormal mood states, including bipolar
disorder, there are quite a few methodological hurdles that
are yet to be overcome. One of the principal areas of concern
relates to the variability and inconsistency of the nature
of HPT axis abnormalities documented among patients
with these disorders. Much of this stems from inadequate
sample sizes, diagnostic heterogeneity, lack of proper con-
trols for confounding factors, and improper standardization
of thyroid function tests [5]. Moreover, given the unique
organization of brain thyroid systems, peripheral measures
of thyroid function may not adequately characterise central
thyroid metabolism [1]. A clearer understanding of the role
of HPT axis dysfunction in bipolar disorder is unlikely to
emerge if these aspects of study-designs are not addressed.
Additionally, the bulk of research on neurobiological mech-
anisms underlying the thyroid-mood disorder link has been
conducted among animals. Studies among mood disordered
subjects are very few and limited to those with depression.
The methods employed to assess CNS neurotransmitter
function have also varied considerably. Therefore, more
methodologically sound studies among clinical subjects
are required to assess potential interactions between these
neurochemical systems in the CNS and thyroid functions
[2, 137].
11. Conclusions andFutureDirections
There is now more or less incontrovertible evidence that,
apart from their developmental eﬀects on the CNS, thyroid
hormones have major eﬀects on the metabolic activity of
the mature brain. Mood disorders are intimately associated
with suboptimal thyroid function. Although comparatively
less investigated, increasing evidence has shown that HPT
axis dysfunction is relevant to the aetiopathogenesis, course,
treatment,andoutcomeofbipolardisorder.Hypothyroidism
either overt or more commonly subclinical appears to the
commonest abnormality found among patients with bipolar
disorder. It is also likely that the prevalence of thyroid
dysfunction is greater in patients with rapid cycling and
more refractory forms of the disorder. Lithium has potent
anti-thyroid eﬀects and can induce hypothyroidism among
patients on this treatment; alternatively, it can exacerbate
a preexisting hypothyroid state. Even minor perturbations
of the HPT axis in the normal range have the potential to
aﬀect the outcome of bipolar disorder. Awareness of this
fact is required among clinicians, and patients should be
carefully monitored and managed for HPT axis dysfunction.
Supplementation with high dose T4 can be considered in
some patients, refractory to standard measures of treatment.
Genetic, neuroimaging, and neurotransmitter studies are
providing newer insights into the complex interactions
between HPT function and bipolar disorder.
Although current research, especially preclinical, re-
search has provided strong leads, the precise cellular and
molecular mechanisms underlying the role of thyroid hor-
mones in pathophysiology and treatment of mood disorders
a r es t i l lt ob ed e l i n e a t e d .F u t u r ea t t e m p t sn e e dt oﬁ l lt h i sg a p
by focusing on translational studies, which can successfully
extend preclinical ﬁndings to the clinical realm of bipolar
disorder, in the true spirit of “bench-to-bedside” research.
Additionally, the clinical component of future research needs
toidentifythosepatientswithbipolardisorderswhoaremost
likely to beneﬁt from therapeutic manipulations of the HPT
axis, for example, by focusing on genetic markers. Together,Journal of Thyroid Research 9
these two strands of research can not only enhance our
understanding of the thyroid-bipolar disorder connection,
but also lead to more optimal ways of managing this
potentially disabling condition.
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